Copy-number variation of MCL1 predicts overall survival of non-small-cell lung cancer in a Southern Chinese population

详细信息    查看全文

• 作者：Jieyun Yin ; Yangkai Li ; Hao Zhao ; Qin Qin ; Xiaorong Li ; Jiao Huang ; Yun Shi ; Shufang Gong ; Li Liu ; Xiangning Fu ; Shaofa Nie and Sheng Wei
• 刊名：Cancer Medicine
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：5
• 期：9
• 页码：2171-2179
• 全文大小：307K
• ISSN：2045-7634

文摘

BCL2L1 and MCL1 are key anti-apoptotic genes, and critical for cancer progression. The prognostic values of BCL2L1 and MCL1 copy-number variations (CNVs) in non-small-cell lung cancer (NSCLC) remain largely unknown. Somatic CNVs in BCL2L1 and MCL1 genes were tested in tumor tissues from 516 NSCLC patients in southern China; afterward, survival analyses were conducted with overall survival (OS) as outcome. Additionally, the associations between CNVs and mRNA expression levels were explored using data from 986 NSCLC patients in the Cancer Genome Atlas project. It was found that amplifications of BCL2L1 and MCL1 were associated with unfavorable OS of NSCLC, with adjusted hazards ratio of 1.62 (95% confident interval [CI] = 1.10–2.40; P = 0.015) and 1.39 (95% CI = 1.05–1.84; P = 0.020), respectively. Amplifications of MCL1, but not BCL2L1, were related with higher mRNA expression levels of corresponding gene, compared with non-amplifications (P = 0.005). Interestingly, after incorporating with MCL1 CNV status, clinical variables (age, sex, TNM stage, and surgical approach) showed an improved discriminatory ability to classify OS (area under curve increased from 72.2% to 74.1%; P = 0.042, DeLong's test). Overall, MCL1 CNV might be a prognostic biomarker for NSCLC, and additional investigations are needed to validate our findings.